# EDGAR Filing Document

**Accession Number:** 0001817229
**File Stem:** 0000000000-25-010639
**Filing Date:** 2025-9
**Character Count:** 2198
**Document Hash:** cbc3cdb82b26ddb80f6accd5aa1d8899
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-010639.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0000000000-25-010639

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250930

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vor Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001817229
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811591163
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-290490

**BUSINESS ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-655-6580

**MAIL ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-25-215602

## Text-Extract

```

                                                           September 30, 2025

Jean-Paul Kress, M.D.
President and Chief Executive Officer
Vor Biopharma Inc.
500 Boylston Street, Suite 1350
Boston, Massachusetts 02116

       Re: Vor Biopharma Inc.
           Registration Statement on Form S-3
           Filed September 24, 2025
           File No. 333-290490
Dear Jean-Paul Kress M.D.:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Katie Kazem

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._